Intervention

disitamab vedotin

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting1

Common conditions16

Lead sponsors shown2

Clinical trials

3 shown

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialNCT06278870 · 2023-09-06

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsNCT06157892 · 2024-05-20

ACTIVE_NOT_RECRUITING

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2NCT06003231 · 2023-11-14

ACTIVE_NOT_RECRUITING

Common conditions

Advanced Breast Cancer1 Advanced Gastric Cancer1 Breast Neoplasms1 Carcinoma, Non-Small-Cell Lung1 Endometrial Neoplasms1 First-line Treatment1 Gastroesophageal Junction Adenocarcinoma1 Head and Neck Neoplasms1 HER2 Low Breast Neoplasms1 HER2 Positive Breast Neoplasms1 HER2-positive Metastatic Breast Cancer1 Metastatic Breast Cancer1 Metastatic Gastric Cancer1 Ovarian Neoplasms1 Stomach Neoplasms1 Triple Negative Breast Neoplasms1

Leading sponsors

Seagen, a wholly owned subsidiary of Pfizer2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1

Trial status mix

ACTIVE_NOT_RECRUITING2

RECRUITING1

Phase mix

PHASE22

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.